News

Consistent with prior guidance, earlier this year, Mast Therapeutics submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA), together with the protocol

INNs facilitate the identification of active pharmaceutical ingredients, and each INN is a globally recognized unique name. As a novel, orally available, selective tyrosine kinase inhibitor of the

HealthPatch MD can be used with Medidata’s industry-leading technology platform (Medidata Clinical Cloud) and its mobile app for patient-reported outcomes (Medidata Patient Cloud) to further remote patient monitoring,

ZipDose products allow people to take their medications with greater ease, potentially increasing adherence and improving symptom management. According to the company, these products achieve dosage strengths that

Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies. Can-Fite reports today that it received positive pre-clinical data

Endo will collaborate with Trimel on all regulatory and clinical development activities regarding Natesto, which was approved by the U.S. Food and Drug Administration (FDA) in May of

A total of 46 male and female volunteers ranging from 45 to 80 years of age were included in the randomized, double-blind, placebo-controlled cross-over trial. The company said

The research alliance will focus on discovery, research and development of new drugs for some of the common and debilitating gastrointestinal diseases and disorders such as irritable bowel

The product is based on the latest molecular iodine technology designed to help free women from the burden of breast discomfort by addressing the underlying causes of a